Dr.Dieter A. Wolf
Dr. Wolf studied medicine at the University in Munich, Germany. After postdoctoral work at Harvard Medical School and Stanford University School of Medicine, he joined the Department of Cancer Cell Biology at Harvard as an Assistant Professor in 1998. In 2007, Dr. Wolf moved to Sanford-Burnham Medical Research Institute as Professor and Director of Proteomics. In 2015, Dr. Wolf was recruited to Xiamen University’s School of Pharmaceutical Sciences as a Foreign 1000 Talents Professor.
Dr. Wolf’s research focuses on protein quality control and associated stress response pathways and their utility as cancer drug targets. Among the most significant achievements were the identification of BTB proteins as substrate adapters of cullin3-based ubiquitin ligases and studies on the regulation of cullin-RING ubiquitin ligases by deneddylation. The lab has also addressed the proteolytic control of the prostate tumor suppressor p27. A major achievement was the identification of compound SMIP004 as an inhibitor of 27 degradation and an inducer of cancer cell-selective apoptosis in prostate cancer cells through Unfolded Protein Response signaling downstream of mitochondrial inhibition.
Proteomic technology employing LC-MS/MS for comprehensive protein profiling and analysis of the dynamics of protein complexes has been central to this work. Among the most recent achievements using proteomicswere the identification of the “translasome“ as a direct physical link between the protein synthesis and degradation machineries, the demonstration that CAND1 is a factor controlling the dynamic assembly of cullin-RING ubiquitin ligases, a systems view of gene expression in response to oxidative stress, and quantitative profiling of drug effector pathways in prostate cancer cells. This research also employs network-based and mathematical modeling approaches.
At Xiamen University, Dr. Wolf’s lab will focus on castration-resistant prostate cancer - a major health issue in China and beyond - establishing patient-derived xenograft models, in vivo loss-of-function screens, and cancer proteomics for the identification of novel drug targets. A second focus concerns mechanisms controlling protein synthesis, their roles in cancer, and their potential as novel drug targets.
Wolf, D.A. (2014) Is reliance on mitochondrial respiration a chink in the armor of therapy-resistant cancer? Cancer Cell 26, 788-795
Yang C.-C.; Chung, A.; Brill, L.M.; Williams, R.; Wolf, D.A. (2014) Systems analysis of the prostate tumor suppressor NKX3.1 supports roles in DNA repair and luminal cell differentiation. F1000Research 2014, 3:115
Rico-Bautista, E.; Zhu, W.; Kitada, S.; Ganapathy, S.; Lau, E.; Krajewski, S.; Ramirez, J.; Bush, J.A.; Yuan, Z.; Wolf, D.A.(2013) Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via unfolded protein response signaling. Oncotarget 4, 1212-1229 -
Wu, S..; Zhou, W.; Nhan, T.; Toth J.I.; Petroski, M.D.; Wolf, D.A. (2013) CAND1 controls in vivo dynamics of the cullin 1-RING ubiquitin ligase repertoire. Nature Communications 4, 1642
Bauer, F.; Matsuyama, A.; Candiracci, J.; Dieu, M.; Scheliga, S.; Wolf, D.A.; Yoshida, M.; Hermand, D. (2012) Translational control of cell division by elongator. Cell Reports 1, 424-433 - This article was cited here
Lackner, D.H.; Schmidt, M.W.; Wu, S.; Wolf, D.A., Bähler, J. (2012) Regulation of transcriptome, translation, and proteome in response to environmental stress in fission yeast. Genome Biology 13:R25
Keren-Kaplan, T.; Attali, I., Motamedchaboki, K.; Davis, B.A.; Tanner, N., Reshef, Y., Laudon, E.; Kolot, M.; Levin-Kravets, O.; Kleifeld, O.; Glickman, M.; Horazdovsky, B.F.; Wolf, D.A., Prag, G. (2012) Synthetic biology approach to reconstituting the ubiquitylation cascade in bacteria. EMBO J., 31, 378 - 390
Rico-Bautista, E.; Yang, C.-C.; Lu, L.; Roth, G.P.; Wolf, D.A. (2010) Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biology 8:153